Positron emission tomography (PET) myocardial perfusion imaging (MPI) is an examination that
helps to assess the function and perfusion of the heart. Completion of this examination
requires the injection of a small dose of a radiotracer (a radioactive substance).
PET MPI is a state-of-the-art non-invasive cardiac imaging tool. The main goal of the PET MPI
examination is to assess if one or more of the arteries feeding blood to your heart are
blocked. This examination replaces an older technology (single photon emission computed
tomography, or SPECT), and allows the obtention of more accurate information, and new
information that the older SPECT technology did not assess. The radiation dose received as
part of the procedure is also smaller with PET versus SPECT.
One of the substances which can be used for PET MPI is called N-13 ammoniac (NH3). For this
clinical study, NH3 which will be produced at the Centre de Recherche du Centre Hospitalier
de l'Université de Montréal (CRCHUM), per the standards and methods prescribed by Health
Canada. NH3 is not currently approved for clinical use by Health Canada. It is thus
considered and experimental substance in the context of this study.
Participants will undergo PET MPI with the CRCHUM NH3. The PET MPI procedure itself is not an
experimental procedure and is not part of the research protocol. Only the use of NH3 produced
at the CRCHUM is experimental.
The main objective of this research study is to validate the production process and assess
the safety of the NH3 produced at the CRCHUM cyclotron. Secondary objectives include the
assessment of prescription practices amongst physicians who refer patients for PET MPI, and
how they will change over time.
Phase:
Phase 4
Details
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)